# US 2020/0390724 A1 · Treatment of ocular diseases with ophthalmic tapinarof compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390724 A1
- Document ID: US20200390724A1
- Status: Published application
- Kind: A1
- Application number: 16/935,452
- Filed: 2020-07-22
- Published: 2020-12-17
- Earliest claimed: 2019-06-17
- Assignees: Sol-Gel Technologies Ltd.
- Applicants: Sol-Gel Technologies Ltd.
- Inventors: Moshe ARKIN; Marcel ZIGHELBOIM
- Web page: https://patentgrep.com/patent/US20200390724A1

## CPC

- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention and/or alleviation of the symptoms of an ocular inflammatory disease or an ocular degeneration disease selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED), age-related macular degeneration and combinations thereof.

## Claims

### Claim 1

A topical ophthalmic composition for the treatment, prevention and/or amelioration of an ocular inflammatory disease or ocular degeneration disease, comprising from about 0.01% w/w to about 10.0% w/w tapinarof and a carrier suitable for topical ophthalmic administration.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the ocular inflammatory disease or the ocular degeneration disease is selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED) and combinations thereof.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising from about 0.01% w/ to about 10% w/w at least one additional active agent selected from a weak corticosteroid, an immune suppressant, an immune mediator, an antimuscarinic agent, a VGF inhibitor, an NSAID, a cytotoxic drug, a corticosteroid-sparing immunosuppressant, a TNF-α inhibitor, an antibiotic and combinations thereof.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said at least one additional active agent is selected from loteprednol etabonate, prednisolone acetate, triamcinolone acetate, cyclosporin, lifitegrast, atropine, homatropine, ranibizumab, aflibercept, pegaptanib, nepafenac, meloxicam, diclofenac, bendazac, ketorolac, oxyphenbutazone, bromfenac, flurbiprofen, pranoprofen, suprofen, indomethacin, celecoxib, rofecoxib, valdecoxib, parecoxib, etoricoxib, nimesulide, etodolac, nabumetone, adalimumab, chlorambucil, cyclophosphamide, methotrexate, azathioprine, levofloxacin, gatifloxacin, moxifloxacin, ofloxacin and combinations thereof.

### Claim 5 (depends on 1)

A dosage form comprising the composition of claim 1, wherein the composition is formulated in a dosage form selected from an ointment, a suspension, a cream, a spray, a lotion, a gel, an emulsion, a solution, an elixir, a tincture, a paste, a foam and drops.

### Claim 6 (depends on 3)

A dosage form comprising the composition of claim 3, wherein the composition is formulated in a dosage form selected from an ointment, a suspension, a cream, a spray, a lotion, a gel, an emulsion, a solution, an elixir, a tincture, a paste, a foam and drops.

### Claim 7 (depends on 5)

The dosage form of claim 5, wherein the solution comprises nanomicelles comprising tapinarof.

### Claim 8 (depends on 6)

The dosage form of claim 6, wherein the solution comprises nanomicelles comprising tapinarof.

### Claim 9 (depends on 1)

A method of treatment, prevention and/or alleviation of an ocular inflammatory disease or ocular degeneration disease, comprising topically administering to the eyes of a subject in need thereof a therapeutically effective amount of a composition of claim 1, wherein the composition is formulated as an ophthalmic ointment, suspension, solution, drops, cream or foam.

### Claim 10 (depends on 9)

The method of claim 9, wherein the ocular inflammatory disease or the ocular degeneration disease is selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED), and combinations thereof.

### Claim 11 (depends on 9)

The method of claim 9, wherein the treatment comprises once daily or twice daily topical administration to a subject in need thereof of a therapeutically effective amount of said composition.

### Claim 12 (depends on 3)

A method of treatment, prevention and/or alleviation of an ocular inflammatory disease or ocular degeneration disease, comprising topically administering to the eyes of a subject in need thereof a therapeutically effective amount of a composition of claim 3, wherein the composition is formulated as an ophthalmic ointment, suspension, solution, drops, cream or foam.

### Claim 13 (depends on 12)

The method of claim 12, wherein the ocular inflammatory disease or the ocular degeneration disease is selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED), and combinations thereof.

### Claim 14 (depends on 12)

The method of claim 12, wherein the treatment comprises once daily or twice daily topical administration to a subject in need thereof of a therapeutically effective amount of said composition.

### Claim 15 (depends on 12)

The method of claim 12, wherein tapinarof and the at least one additional active agent exhibit an additive or synergistic effect, thereby allowing to reduce the amounts of the active agents in the composition.

### Claim 16 (depends on 1)

A regimen of administration comprising the once daily or twice daily administration to the eyes of a patient in need thereof of a therapeutically effective amount of the composition of claim 1 until remission or alleviation of the ocular inflammatory disease or the ocular degeneration disease symptoms.

### Claim 17 (depends on 3)

A regimen of administration comprising the once daily or twice daily administration to a patient in need thereof a therapeutically effective amount of the composition of claim 3 remission or alleviation of the ocular inflammatory disease or the ocular degeneration disease symptoms.

### Claim 18 (depends on 16)

The regimen of claim 16, wherein the ocular inflammatory disease or the ocular degeneration disease is selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED), and combinations thereof.

### Claim 19 (depends on 17)

The regimen of claim 17, wherein the ocular inflammatory disease or the ocular degeneration disease is selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED), and combinations thereof.

### Claim 20 (depends on 5)

A kit comprising one or more dosage forms of claim 5 and instructions for use.

### Claim 21 (depends on 6)

A kit comprising one or more dosage forms of claim 6 and instructions for use
